ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
OncoSec Doses First Patient in KEYNOTE-890 Phase 2 Clinical Trial
November 10, 2018OncoSec announced the first patient has been treated in KEYNOTE-890, a Phase 2 clinical trial for the treatment of late-stage triple negative breast cancer (TNBC) with TAVO (intratumoral plasma encoded IL-12, or tavokinogene telseplasmid, plus electropora -
OncoSec Doses First Patient in KEYNOTE-890 Phase 2 Clinical Trial
November 10, 2018OncoSec announced the first patient has been treated in KEYNOTE-890, a Phase 2 clinical trial for the treatment of late-stage triple negative breast cancer (TNBC) with TAVO (intratumoral plasma encoded IL-12, or tavokinogene telseplasmid, plus electropora -
OncoSec Appoints Chief Clinical Development Officer
October 30, 2018The award was given in recognition of the exemplary contributions to the profession and improvement of society in line with the mission of FAPA in Asia -
OncoSec Announces Positive Data from Trial of ImmunoPulse IL-12, Pembrolizumab
November 09, 2017The updated clinical and correlative immune-focused biomarker data demonstrated a 57% progression free survival (PFS) rate at 15 months with 100% (11/11) duration of response and median PFS not yet reached.
Pharma Sources Insight January 2025
